Finoriq research workspace
Annexon, Inc. (ANNX) Institutional Holdings & 13F Ownership
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines. Review ANNX institutional holders, 13F ownership, and position changes on Finoriq.
Company Snapshot
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis. It is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.
- Company
- Annexon, Inc. (ANNX)
- Ticker
- ANNX
- Market Cap
- $917.5M
- Latest Price
- $5.60
- Industry
- Biotech & Pharma
Annexon, Inc. (ANNX) Top Institutional Holders
Top current 13F holders indexed for Annexon, Inc. (ANNX). Latest period 2026-03-31.
| Rank | Investor | Value | Portfolio | Filing |
|---|---|---|---|---|
| 1 | Polen Capital ManagementCIK 0001034524 | $388,642 | 0.0% | Filing2026-05-14 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.